Trial Profile

A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adagrasib (Primary) ; INCB 099280 (Primary)
Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions
Sponsors Incyte Corporation

Most Recent Events

26 Jun 2024 Status changed from recruiting to active, no longer recruiting.
02 Nov 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 6 Nov 2023 to 10 Jan 2024.
02 Nov 2023 Planned initiation date (estimated date of first participant enrollement) changed from 20 Oct 2023 to 6 Nov 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com